Artemisinin Combination Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031

Artemisinin Combination Therapy Market Trends and Forecast

The future of the global artemisinin combination therapy market looks promising with opportunities in the hospital, clinic markets. The global artemisinin combination therapy market is expected to grow with a CAGR of 8.2% from 2025 to 2031. The major drivers for this market are its demonstrated effectiveness in quickly eliminating parasitemia, alleviating symptoms enhances treatment success rates, and prevent the emergence of drug-resistant malaria strains.

Lucintel forecasts that, within the type category, artemether+lumefantrine is expected to witness the highest growth over the forecast period due to its superior effectiveness and safety in treating uncomplicated malaria.
Within the application category, clinic is expected to witness the higher growth due to treatments are commonly administered in clinics, especially in malaria-endemic regions.
In terms of region, North America will remain the largest region over the forecast period due to the rising number of imported malaria cases and the need for effective treatment options.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy (ACT) market is undergoing rapid transformation, driven by various technological, regulatory, and research developments. These trends reflect the evolving challenges in malaria control, such as drug resistance and affordability, while also highlighting opportunities for innovation and growth in the treatment landscape. The following emerging trends are reshaping the ACT market and pushing it toward more effective, accessible, and sustainable solutions.

• Innovation in Fixed-Dose Combinations: Fixed-dose combinations (FDCs) of artemisinin and other antimalarial drugs are gaining momentum due to their ease of use and improved patient adherence. By combining multiple drugs into a single tablet, FDCs reduce the risk of resistance and improve treatment outcomes. Pharmaceutical companies are developing more efficient FDCs with shorter treatment durations, making them highly effective for large-scale malaria control programs. This trend is expected to drive the demand for ACTs, especially in countries with high malaria transmission.

• Growing Focus on Resistance Management: As resistance to artemisinin-based therapies becomes a growing concern, researchers are focused on developing new drugs and strategies to overcome this issue. Resistance management initiatives, including new ACT combinations and alternative drugs, are becoming a significant part of the market landscape. This trend is shaping research directions, leading to innovative drug development that can preserve the efficacy of ACT therapies in regions affected by drug-resistant malaria strains, particularly in Southeast Asia and sub-Saharan Africa.

• Public-Private Partnerships: The collaboration between governments, international organizations, and private pharmaceutical companies is essential to improving ACT access in malaria-endemic regions. Public-private partnerships (PPPs) are key to ensuring the affordability and availability of ACTs in low-income countries. These partnerships have led to increased production and distribution, as well as the development of novel ACT formulations. Through PPPs, stakeholders aim to increase global supply chains, reduce costs, and expand access to ACT therapies in regions most affected by malaria.

• Advances in Delivery Mechanisms: The ACT market is witnessing advancements in drug delivery systems aimed at improving treatment efficacy and patient compliance. Innovations such as controlled-release formulations and injectable ACTs are being explored to provide more efficient dosing regimens. This trend is expected to enhance the effectiveness of ACTs, especially in areas with limited access to healthcare or where oral treatments may not be feasible. These innovations are helping to address the logistical challenges of malaria treatment delivery.

• Digital Health Integration: Digital health technologies are being integrated into malaria control programs to improve monitoring, diagnosis, and treatment adherence. Mobile health applications, telemedicine, and data analytics are increasingly used to track the effectiveness of ACT therapies in real time. Digital platforms also support patient education, increasing awareness of malaria prevention and treatment. This trend is reshaping the landscape of ACT distribution and monitoring, enhancing the global response to malaria.

The Artemisinin Combination Therapy (ACT) market is being shaped by a series of emerging trends that reflect the increasing need for innovative solutions in malaria treatment and control. Innovations like fixed-dose combinations, resistance management strategies, and digital health integration are all contributing to more effective, accessible, and sustainable treatment options. Public-private partnerships and advances in drug delivery mechanisms further enhance the scalability of ACT programs globally.

Recent Developments in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy (ACT) market is witnessing significant developments that reflect the evolving global response to malaria. These developments are influenced by new therapeutic advancements, international collaborations, and regulatory updates aimed at enhancing the efficacy, affordability, and accessibility of ACTs. The following key developments highlight how the ACT market is transforming to address current and future challenges in malaria treatment.

• Introduction of Novel ACT Formulations: Recent developments in the ACT market include the introduction of novel drug formulations that combine artemisinin with new partners, such as pyronaridine and tafenoquine. These new combinations are being developed to combat drug resistance and improve treatment efficacy. For example, the introduction of pyronaridine-artesunate as an alternative to traditional ACTs addresses concerns related to artemisinin resistance in Southeast Asia. These new formulations are expected to provide more durable solutions to malaria treatment.

• Expansion of Generic ACT Production: India, China, and several other countries have ramped up the production of generic ACTs, which are helping to make malaria treatment more affordable and accessible in endemic regions. The availability of affordable generic ACTs is critical to the success of malaria control programs in low-income countries. This trend is contributing to the wider distribution of ACTs, especially through government health programs, reducing the economic burden of malaria treatment.

• Enhanced Global Collaboration and Funding: Global collaborations and funding from organizations such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) and the World Health Organization (WHO) have increased the availability of ACTs in endemic regions. These collaborations focus on scaling up the distribution of ACTs, improving healthcare infrastructure, and investing in malaria research. Enhanced funding mechanisms and partnerships have played a crucial role in increasing access to ACTs in sub-Saharan Africa and other high-burden regions.

• Increased Focus on Malaria Elimination: Several countries have committed to malaria elimination by 2030, and ACT is central to these national strategies. Countries such as China and India are advancing malaria elimination efforts by strengthening ACT supply chains, improving diagnosis and treatment coverage, and integrating ACT use into broader public health programs. These efforts are accelerating the deployment of ACTs in areas with low but persistent malaria transmission, helping to reduce malaria transmission rates and move closer to the goal of global eradication.

• Regulatory Advancements in ACT Approvals: Regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) have recently approved new ACT combinations and formulations. These regulatory advancements streamline the approval process for ACTs, ensuring quicker access to innovative therapies. With increasing approval of new combinations and alternative drugs, the global market for ACTs is diversifying, offering more options for malaria treatment, especially in areas facing artemisinin resistance.

Recent developments in the Artemisinin Combination Therapy (ACT) market are focused on enhancing drug efficacy, accessibility, and addressing challenges like drug resistance. The introduction of novel formulations, increased generic production, and global collaborations has expanded the availability of ACTs in malaria-endemic regions. Efforts toward malaria eradication and advancements in regulatory approvals are reshaping the market, while innovations in ACT formulations are improving treatment outcomes.

Strategic Growth Opportunities for Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy (ACT) market is poised for growth, driven by strategic opportunities across various applications. These growth opportunities are linked to innovations in drug formulations, global health initiatives, and the expanding focus on malaria eradication. The following are key growth opportunities by application in the ACT market, each playing a critical role in shaping the future of malaria control and treatment.

• Strengthening Malaria Control Programs: A significant growth opportunity lies in strengthening national malaria control programs (NMCPs) in malaria-endemic countries. ACTs play a central role in these programs, where governments are investing in mass drug administration campaigns, integrated vector management, and surveillance systems. Expanding access to ACTs through government-run distribution programs is critical to achieving the World Health Organization’s global malaria targets, particularly in regions such as sub-Saharan Africa.

• Pediatric Malaria Treatment: Pediatric malaria treatment represents a key growth opportunity, with increasing focus on formulating ACTs that are more suitable for children. Efforts are being made to improve the palatability, dosage, and safety of ACTs for pediatric patients, as this group faces higher mortality rates from malaria. The development of pediatric-friendly ACT formulations and combination therapies is expected to drive market growth in countries with high childhood malaria burden.

• Scaling Up Preventative Malaria Treatment: Preventative malaria treatment strategies, such as seasonal malaria chemoprevention (SMC), are gaining momentum. ACTs are integral to these efforts, which involve administering ACTs to individuals in malaria-endemic regions during peak transmission seasons. The scalability of these preventive programs offers significant growth potential for the ACT market, especially in areas where seasonal malaria transmission is a major concern.

• Investment in Malaria Vaccine Programs: While vaccines are not yet a complete solution, their integration with ACT treatments presents a unique growth opportunity. Malaria vaccine initiatives, such as the RTS,S/AS01 vaccine, are complementing ACTs in regions with high malaria transmission. The convergence of vaccines and ACTs creates synergies that could improve malaria control, expanding the market for ACTs and providing new channels for distribution and application.

• Expansion of Malaria Research and Development: The ongoing research into drug-resistant malaria and new therapies presents an opportunity for growth. Investment in R&D for novel ACTs, combination therapies, and alternative treatment regimens is expected to open new market avenues. As new formulations and treatments are developed, these will complement the current ACT landscape and further drive demand.

These applications collectively contribute to a comprehensive approach to malaria control, opening up avenues for growth and reinforcing global efforts to combat malaria. As these opportunities are harnessed, the ACT market is set to become a central pillar of malaria eradication initiatives.

Artemisinin Combination Therapy Market Driver and Challenges

The Artemisinin Combination Therapy (ACT) market is influenced by various drivers and challenges. These include technological advancements in drug development, economic considerations, and regulatory frameworks. On the one hand, advancements in ACT formulations and collaborations in global health have led to increased market demand. On the other hand, challenges like drug resistance and affordability constraints affect its growth potential. Understanding these dynamics is essential to navigating the market’s evolution.
The factors responsible for driving the Artemisinin Combination Therapy market include:
1. Increase in Malaria Cases: The rising incidence of malaria, particularly in sub-Saharan Africa and Southeast Asia, drives the demand for ACTs. With approximately 200 million cases globally, ACTs are critical for controlling outbreaks and improving public health outcomes. The growth in malaria cases in certain regions underscores the need for effective treatment options, supporting the market for ACTs.
2. Government and NGO Support: Governments and international organizations play a pivotal role in funding ACT distribution programs. Agencies like the Global Fund, WHO, and various national health ministries are investing heavily in malaria eradication, increasing the accessibility and availability of ACTs worldwide. This financial and institutional support fosters market expansion, especially in high-burden regions.
3. Advancements in ACT Formulations: Research and development into novel ACT formulations, such as fixed-dose combinations and improved drug delivery mechanisms, are significant drivers. These innovations improve treatment outcomes, reduce side effects, and enhance patient compliance, which makes ACTs more attractive for malaria-endemic countries, boosting market demand.
4. Cost Reduction and Generic Production: The growing production of generic ACTs, particularly by Indian and Chinese pharmaceutical companies, has lowered the cost of malaria treatment. These affordable options are critical for low-income countries, increasing the penetration of ACTs in endemic regions and driving overall market growth.
5. Focus on Malaria Eradication: The global push towards malaria elimination by 2030 provides a strong growth driver for the ACT market. National strategies focused on malaria eradication rely heavily on effective treatment options, with ACTs playing a central role. This focus on eradication ensures sustained demand and strategic investments in the ACT market.
Challenges in the Artemisinin Combination Therapy market are:
1. Drug Resistance: Artemisinin resistance, particularly in Southeast Asia, poses a significant threat to the efficacy of ACTs. The emergence of resistant strains necessitates the development of new ACT combinations and alternatives to maintain effectiveness. Resistance challenges may hinder the widespread use of current ACTs if not addressed.
2. Affordability and Access: While generics have lowered prices, the affordability of ACTs remains a challenge in low-income regions. Issues related to distribution, healthcare infrastructure, and financial barriers affect access to ACTs in the most vulnerable populations, limiting their impact on malaria control.
3. Supply Chain and Distribution Constraints: The global supply chain for ACTs faces logistical challenges, including the timely delivery of drugs to remote and hard-to-reach areas. Inefficient distribution systems and stock outs continue to be barriers, hindering the consistent availability of ACTs when and where they are most needed.
The drivers and challenges in the ACT market are interrelated. While increasing malaria cases and advancements in drug formulations fuel growth, challenges such as resistance and access barriers require attention. Strategic investments and collaborations will be crucial to overcoming these hurdles and ensuring the continued success of ACTs in global malaria control efforts.

List of Artemisinin Combination Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies artemisinin combination therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the artemisinin combination therapy companies profiled in this report include-

• KPC Pharmaceuticals

• Sanofi

• Desano Holdings

• Mylan

• Novartis

Artemisinin Combination Therapy Market by Segment

The study includes a forecast for the global artemisinin combination therapy market by type, application, and region.

Artemisinin Combination Therapy Market by Type [Value from 2019 to 2031]:

• Artemether+Lumefantrine

• Artesunate+Amodiaquine

• Dihydroartemisinin+Piperaquine

• Artesunate+Mefloquine

• Artesunate+Sulfadoxine-Pyrimethamine

• Pyronaridine-Artesunate

• Others

Artemisinin Combination Therapy Market by Application [Value from 2019 to 2031]:

• Hospital

• Clinic

• Other

Artemisinin Combination Therapy Market by Region [Value from 2019 to 2031]:

• North America

• Europe

• Asia Pacific

• The Rest of the World

Country Wise Outlook for the Artemisinin Combination Therapy Market

Artemisinin Combination Therapy (ACT) is the gold-standard treatment for malaria, especially in areas with widespread drug-resistant malaria strains. The market for ACT is growing due to rising malaria incidences, particularly in developing countries, but also due to advancements in drug formulations and production methods. Emerging markets, such as China and India, play a critical role in shaping this growth. Meanwhile, developed countries like the United States, Germany, and Japan are focused on supporting global health initiatives and investing in innovative ACT research. Here we explore the key developments, trends, growth opportunities, and challenges in the ACT market in the United States, China, Germany, India, and Japan.

• United States: The United States has seen a continued focus on supporting global malaria eradication efforts. A key development in the ACT market is the government’s investment in research and development of new drug formulations. The U.S. is also a major supplier of ACT medicines through organizations like the U.S. Agency for International Development (USAID). However, domestically, malaria cases are relatively low, so ACT demand is mainly driven by U.S.-funded international programs. The U.S. is increasingly involved in the deployment of newer ACT formulations in sub-Saharan Africa and Southeast Asia, with an emphasis on cost-effective and efficient therapies.

• China: China remains a critical player in the global ACT market. The country has significantly reduced its malaria burden, but it continues to invest heavily in malaria research. China’s advancements in manufacturing and producing artemisinin-based therapies have led to cost reductions, making ACT more accessible across Southeast Asia and sub-Saharan Africa. In addition, Chinese companies are increasingly involved in clinical trials to develop next-generation ACT treatments. The government is also focusing on integrating ACT with other public health programs to eradicate malaria by 2030, positioning China as a key hub for innovation and supply in the ACT market.

• Germany: Germany’s role in the ACT market is largely driven by its commitment to international development and malaria eradication. The country supports the global roll-out of ACT through collaborations with international organizations, including the World Health Organization (WHO). German pharmaceutical companies are also active in improving the efficacy and affordability of ACT, with investments in the development of fixed-dose combination therapies (FDCs). Furthermore, Germany is a key player in malaria research, with its scientific community focusing on the development of new ACT formulations to combat emerging resistance.

• India: India, with its large population and high malaria burden, is both a producer and a consumer of ACT. The country has focused on increasing access to ACT for its domestic population, which is critical for controlling malaria transmission. Indian pharmaceutical companies, including Cipla and Dr. Reddy’s Laboratories, play a key role in producing affordable generic ACTs, which are distributed through government programs. India is also engaged in developing more efficient and robust ACT formulations to combat drug resistance, with ongoing efforts to improve drug delivery and minimize side effects in the population.

• Japan: Japan’s involvement in the ACT market is primarily through international development and research. While domestic malaria cases are extremely low, Japan is heavily invested in global malaria eradication efforts. Japan’s pharmaceutical industry has made significant contributions to the ACT market through collaborations and research on more effective therapies. Moreover, Japan supports malaria control through organizations like the Japan International Cooperation Agency (JICA), which is focused on funding ACT distribution in malaria-endemic regions, particularly in Southeast Asia and Africa. Japan also plays a crucial role in improving malaria diagnostics and treatment protocols.

Features of the Global Artemisinin Combination Therapy Market

Market Size Estimates: Artemisinin combination therapy market size estimation in terms of value ($M).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Artemisinin combination therapy market size by type, application, and region in terms of value ($M).
Regional Analysis: Artemisinin combination therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the artemisinin combination therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the artemisinin combination therapy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for artemisinin combination therapy market?
Answer: The global artemisinin combination therapy market is expected to grow with a CAGR of 8.2% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the artemisinin combination therapy market?
Answer: The major drivers for this market are its demonstrated effectiveness in quickly eliminating parasitemia, alleviating symptoms enhances treatment success rates, and prevent the emergence of drug-resistant malaria strains.
Q3. What are the major segments for artemisinin combination therapy market?
Answer: The future of the artemisinin combination therapy market looks promising with opportunities in the hospital, clinic markets.
Q4. Who are the key artemisinin combination therapy market companies?
Answer: Some of the key artemisinin combination therapy companies are as follows:

• KPC Pharmaceuticals

• Sanofi

• Desano Holdings

• Mylan

• Novartis

Q5. Which artemisinin combination therapy market segment will be the largest in future?
Answer: Lucintel forecasts that artemether+lumefantrine is expected to witness the highest growth over the forecast period due to its superior effectiveness and safety in treating uncomplicated malaria.
Q6. In artemisinin combination therapy market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to the rising number of imported malaria cases and the need for effective treatment options.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.